Assessing the cost-effectiveness of prevention.
In an era of limited resources, cost-effectiveness analysis and cost-benefit analysis (CEA/CBA) can be significant policy-making aids. Because the often stated belief that prevention is cost-effective has not been systematically examined, we surveyed about 250 CEA/CBA articles concerning prevention. We found that few authors have followed generally accepted methodological standards, which raised questions concerning the validity of their findings and conclusions. In addition, prevention itself is a problem in CEA/CBA because of such factors as the long intervals between interventions and outcomes, problems which have rarely been considered in the CEA/CBA prevention literature. At the same time, a number of high quality studies concerning prevention indicates that United States policy makers have not aggressively pursued significant opportunities to improve health through prevention, for example by immunizing the elderly and by screening for and treating hypertension. We recommend that analysts follow general methodological principles in CEA/CBA prevention studies to assure both valid and credible results.
D003362:Cost-Benefit Analysis; D006291:Health Policy / Q000191:economics; D006293:Health Promotion / Q000191:economics; D006801:Humans; D006973:Hypertension / Q000517:prevention & control; D008403:Mass Screening / Q000191:economics; D009369:Neoplasms / Q000517:prevention & control; D011314:Preventive Health Services / Q000191:economics*; D011322:Primary Prevention / Q000191:economics*